• Title/Summary/Keyword: Non-small-cell lung

Search Result 972, Processing Time 0.032 seconds

The effects of adjuvant therapy and prognostic factors in completely resected stage IIIa non-small cell lung cancer (비소세포 폐암의 근치적 절제술 후 예후 인자 분석 및 IIIa 병기에서의 보조 요법의 효과에 대한 연구)

  • Cho, Se Haeng;Chung, Kyung Young;Kim, Joo Hang;Kim, Byung Soo;Chang, Joon;Kim, Sung Kyu;Lee, Won Young
    • Tuberculosis and Respiratory Diseases
    • /
    • v.43 no.5
    • /
    • pp.709-719
    • /
    • 1996
  • Background: Surgical resection is the only way to cure non-small cell lung cancer(NSCLC) and the prognosis of NSCLC in patients who undergo a complete resection is largely influenced by the pathologic stage. After surgical resection, recurrences in distant sites is more common than local recurrences. An effective postoperative adjuvant therapy which can prevent recurrences is necessary to improve long tenn survival Although chemotherapy and radiotherapy are still the mainstay in adjuvant therapy, the benefits of such therapies are still controversial. We initiated this retrospective study to evaluate the effects of adjuvant therapies and analyze the prognostic factors for survival after curative resection. Method: From 1990 to 1995, curative resection was perfomled in 282 NSCLC patients with stage I, II, IIIa, Survival analysis of 282 patients was perfonned by Kaplan-Meier method. The prognostic factors, affecting survival of patients were analyzed by Cox regression model. Results: Squamous cell carcinoma was present in 166 patients(59%) ; adenocarcinoma in 86 pmients(30%) ; adenosquamous carcinoma in II parients(3.9%); and large cell undifferentiated carcinoma in 19 patients(7.1%). By TNM staging system, 93 patients were in stage I; 58 patients in stage II ; and 131 patients in stage rna. There were 139 postoperative recurrences which include 28 local and 111 distant failures(20.1% vs 79.9%). The five year survival rate was 50.1% in stage I ; 31.3% in stage II ; and 24.1% in stage IIIa(p <0.0001). The median survival duration was 55 months in stage I ; 27 months in stage II ; and 16 months in stage rna. Among 131 patients with stage rna, the median survival duration was 19 months for 81 patients who received postoperative adjuvant chemotherapy only or cherne-radiotherapy and 14 months for the other 50 patients who received surgery only or surgery with adjuvant radiotherapy(p=0.2982). Among 131 patients with stage IIIa, the median disease free survival duration was 16 months for 21 patients who received postop. adjuvant chemotherapy only and 4 months for 11 patients who received surgery only(p=0.0494). In 131 patients with stage IIIa, 92 cases were in N2 stage. The five year survival rate of the 92 patients with N2 was 25% and their median survival duration was 15 months. The median survival duration in patients with N2 stage was 18 months for those 62 patients who received adjuvant chemotherapy and 14 months for the other 30 patients who did not(p=0.3988). The median survival duration was 16 months for those 66 patients who received irradiation and 14 months for the other 26 patients who did not(p=0.6588). We performed multivariate analysis to identify the factors affecting prognosis after complete surgical resection, using the Cox multiple regression model. Only age(p=0.0093) and the pathologic stage(p<0.0001) were significam prognostic indicators. Conclusion: The age and pathologic stage of the NSCLC parients are the significant prognostic factors in our study. Disease free survival duration was prolonged with statistical significance in patients who received postoperative adjuvant chemotherapy but overall survival duration was not affected according to adjuvant therapy after surgical resection.

  • PDF

Anticancer Activity of the Branch Extracts from Vaccinium oldhamii through Cyclin D1 Proteasomal Degradation in Human Cancer Cells

  • Park, Su Bin;Kim, Ha Na;Park, Gwang Hun;Son, Ho-Jun;Eo, Hyun Ji;Song, Jeong Ho;Song, Hun Min;Park, Ji Ae;Jeong, Jin Boo
    • Korean Journal of Plant Resources
    • /
    • v.31 no.3
    • /
    • pp.218-227
    • /
    • 2018
  • In this study, we investigated the effect of the extracts from Vaccinium oldhamii on cell proliferation and the regulatory mechanisms of cyclin D1 protein level in human cancer cells. The branch extracts from Vaccinium oldhamii (VOB) showed higher inhibitor effect against the cell growth than leave extracts (VOL) and fruit extracts (VOF) in human colorectal cancer, breast cancer, prostate cancer, non-small lung cancer, pancreatic cancer and liver cancer cells. In addition, VOB decreased cyclin D1 level at both protein and mRNA level. MG132 treatment attenuated VOB-mediated cyclin D1 downregulation. A point mutation of threonine-286 to alanine attenuated cyclin D1 degradation by VOB. In addition, the inhibition of nuclear export by leptomycin B (LMB) attenuated cyclin D1 degradation by VOB. But, the treatment of PD98059 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), LiCl ($GSK3{\beta}$ inhibitor), LY294002 (PI3K inhibitor) or BAY 11-7082 ($I{\kappa}K$ inhibitor) did not affect VOB-induced cyclin D1 degradation. In conclusion, VOB induced cyclin D1 degradation through redistribution of cyclin D1 from the nucleus to cytoplasm via T286 phosphorylation of cyclin D1, which resulted in the inhibition of cancer cell proliferation.

Anti Tumoral Properties of Punica granatum (Pomegranate) Seed Extract in Different Human Cancer Cells

  • Seidi, Khaled;Jahanban-Esfahlan, Rana;Abasi, Mozhgan;Abbasi, Mehran Mesgari
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.17 no.3
    • /
    • pp.1119-1122
    • /
    • 2016
  • Background: Punica granatum (PG) has been demonstrated to possess antitumor effects on various types of cancer cells. In this study, we determined antiproliferative properties of a seed extract of PG (PSE) from Iran in different human cancer cells. Materials and Methods: A methanolic extract of pomegranate seeds was prepared. Total phenolic content (TPC) and total flavonoid content (TFC) were assessed by colorimetric assays. Antioxidant activity was determined with reference to DPPH radical scavenging activity. The cytotoxicity of different doses of PSE (0, 5, 20, 100, 250, 500, $1000{\mu}g/ml$) was evaluated by MTT assays with A549 (lung non small cell carcinoma), MCF-7 (breast adenocarcinoma), SKOV3 (ovarian cancer cells), and PC-3 (prostate adenocarcinoma) cells. Results: Significant (P<0.01) or very significant (P<0.0001) differences were observed in comparison to negative controls at all tested doses ($5-1000{\mu}g/ml$). In all studied cancer cells, PSE reduced the cell viability to values below 23%, even at the lowest doses. In all cases, IC50 was determined at doses below $5{\mu}g/ml$. In this regard, SKOV3 ovarian cancer cells were the most responsive to antiproliferative effects of PSE with a maximum mean growth inhibition of 86.8% vs. 82.8%, 81.4% and 80.0% in MCF-7, PC-3 and A549 cells, respectively. Conclusions: Low doses of PSE exert potent antiproliferative effects on different human cancer cells SKOV3 ovarian cancer cells as most and A549 cells ar least responsive regarding cytotoxic effects. However, the mechanisms of action need to be addressed.

Stress-induced Cardiomyopathy during Pulmonary Resection (Takotsubo Syndrome) - A case report -

  • Lee, Seok-Kee;Lim, Seung-Pyung;Yu, Jae-Hyeon;Na, Myung-Hoon;Kang, Shin-Kwang;Kang, Min-Woong;Oh, Hyun-Kong
    • Journal of Chest Surgery
    • /
    • v.44 no.4
    • /
    • pp.294-297
    • /
    • 2011
  • Stress-induced cardiomyopathy is caused by emotional or physical stressors and mimics acute myocardial infarction, though Stress-induced cardiomyopathy is characterized by reversible left ventricular (LV) apical ballooning in the absence of significant coronary artery disease. We describe a 51-year-old male who underwent left upper lobectomy for non-small cell lung cancer, and during which cardiogenic arrest occurred due to stress-induced cardiomyopathy, successfully managed by intra-aortic balloon pumping and extracorporeal membrane oxygenation.

Label/Quencher-Free Detection of Exon Deletion Mutation in Epidermal Growth Factor Receptor Gene Using G-Quadruplex-Inducing DNA Probe

  • Kim, Hyo Ryoung;Lee, Il Joon;Kim, Dong-Eun
    • Journal of Microbiology and Biotechnology
    • /
    • v.27 no.1
    • /
    • pp.72-76
    • /
    • 2017
  • Detection of exon 19 deletion mutation in the epidermal growth factor receptor (EGFR) gene, which results in increased and sustained phosphorylation of EGFR, is important for diagnosis and treatment guidelines in non-small-cell lung cancer. Here, we have developed a simple and convenient detection system using the interaction between G-quadruplex and fluorophore thioflavin T (ThT) for discriminating EGFR exon 19 deletion mutant DNA from wild type without a label and quencher. In the presence of exon 19 deletion mutant DNA, the probe DNAs annealed to the target sequences were transformed into G-quadruplex structure. Subsequent intercalation of ThT into the G-quadruplex resulted in a light-up fluorescence signal, which reflects the amount of mutant DNA. Due to stark differences in fluorescence intensity between mutant and wild-type DNA, we suggest that the induced G-quadruplex structure in the probe DNA can report the presence of cancer-causing deletion mutant DNAs with high sensitivity.

Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways

  • Ihn, Hye Jung;Kim, Ju Ang;Bae, Yong Chul;Shin, Hong-In;Baek, Moon-Chang;Park, Eui Kyun
    • BMB Reports
    • /
    • v.50 no.3
    • /
    • pp.150-155
    • /
    • 2017
  • Non-small-cell lung cancer (NSCLC) is the third most common cancer that spreads to the bone, resulting in osteolytic lesions caused by hyperactivation of osteoclasts. Activating mutations in epidermal growth factor receptor-tyrosine kinase (EGF-TK) are frequently associated with NSCLC, and afatinib is a first-line therapeutic drug, irreversibly targeting EGF-TK. However, the effects of afatinib on osteoclast differentiation and activation as well as the underlying mechanism remain unclear. In this study, afatinib significantly suppressed receptor activator of nuclear factor ${\kappa}B$ (RANK) ligand (RANKL)-induced osteoclast formation in bone marrow macrophages (BMMs). Consistently, afatinib inhibited the expression of osteoclast marker genes, whereas, it upregulated the expression of negative modulator genes. The bone resorbing activity of osteoclasts was also abrogated by afatinib. In addition, afatinib significantly inhibited RANKL-mediated Akt/protein kinase B and c-Jun N-terminal kinase phosphorylation. These results suggest that afatinib substantially suppresses osteoclastogenesis by downregulating RANK signaling pathways, and thus may reduce osteolysis after bone metastasis.

Relationship between the Expression of VEGF, HIF-$1{\alpha}$ and Stage in Non-Small Cell Lung Carcinoma (비소세포성 폐암에서 VEGF, HIF-$1{\alpha}$의 발현과 병기의 상관성)

  • Song, Ho-Seung;Kim, Chul-Woung;Lee, Moo-Sik;Na, Bak-Ju;Lim, Nam-Gu
    • Proceedings of the KAIS Fall Conference
    • /
    • 2009.05a
    • /
    • pp.227-230
    • /
    • 2009
  • 목적 : 비소세포 폐암에서 HIF-$1{\alpha}$, VEGF의 발현과 예후와 관련된 여러 임상적 표지자 및 병리학적 표지자와의 상관관계를 조사하고자 하였다. 방법 : 이들의 예후인자로서의 의미를 알아보고자 외과적으로 절제한 44예의 비소세포 폐암종을 대상으로 VEGF, HIF-$1{\alpha}$에 대한 면역조직화학염색을 시행하였다. 결과 : WHO 분류에 의한 조직학적인 형태인 편평세포암종 28예, 선암종 16예의 비세포성 폐암이 이 연구에 포함되었다. 비소세포성 폐암 24예와 16예에서 VEGF 및 HIF-$1\alpha$이 발현되었다. 결론 : 이 연구에서 VEGF 발현과 병기와의 상관관계, HIF-$1{\alpha}$의 과발현과 병기 사이에서 통계적으로 유의한 상관관계를 볼 수 없었다. 또한 HIF-$1{\alpha}$의 과발현과 VEGF의 발현 사이에 통계학적으로 유의한 관련성이 없었다.

  • PDF

Precision Medicine in Head and Neck Cancer (두경부암에서 정밀의료)

  • Hye-sung Park;Jin-Hyoung Kang
    • Korean Journal of Head & Neck Oncology
    • /
    • v.39 no.1
    • /
    • pp.1-9
    • /
    • 2023
  • Technological advancement in human genome analysis and ICT (information & communication technologies) brought 'precision medicine' into our clinical practice. Precision medicine is a novel medical approach that provides personalized treatments tailored to each individual by precisely segmenting patient populations, based on robust data including a person's genetic information, disease information, lifestyle information, etc. Precision medicine has a potential to be applied to treating a range of tumors, in addition to non-small cell lung cancer, in which precision oncology has been actively practiced. In this article, we are reviewing precision medicine in head and neck cancer (HNC) with focus on tumor agnostic biomarkers and treatments such as NTRK, MSI-H/dMMR, TMB-H and BRAF V600E, all of which were recently approved by U.S. Food and Drug Administration (FDA).

Study of machine learning model for predicting non-small cell lung cancer metastasis using image texture feature (Image texture feature를 이용하여 비소세포폐암 전이 예측 머신러닝 모델 연구)

  • Hye Min Ju;Sang-Keun Woo
    • Proceedings of the Korean Society of Computer Information Conference
    • /
    • 2023.07a
    • /
    • pp.313-315
    • /
    • 2023
  • 본 논문에서는 18F-FDG PET과 CT에서 추출한 영상인자를 이용하여 비소세포폐암의 전이를 예측하는 머신러닝 모델을 생성하였다. 18F-FDG는 종양의 포도당 대사 시 사용되며 이를 추적하여 환자의 암 세포를 진단하는데 사용되는 의료영상 기법 중 하나이다. PET과 CT 영상에서 추출한 이미지 특징은 종양의 생물학적 특성을 반영하며 해당 ROI로부터 계산되어 정량화된 값이다. 본 연구에서는 환자의 의료영상으로부터 image texture 프절 전이 예측에 있어 유의한 인자인지를 확인하기 위하여 AUC를 계산하고 단변량 분석을 진행하였다. PET과 CT에서 각각 4개(GLRLM_GLNU, SHAPE_Compacity only for 3D ROI, SHAPE_Volume_vx, SHAPE_Volume_mL)와 2개(NGLDM_Busyness, TLG_ml)의 image texture feature를 모델의 생성에 사용하였다. 생성된 각 모델의 성능을 평가하기 위해 accuracy와 AUC를 계산하였으며 그 결과 random forest(RF) 모델의 예측 정확도가 가장 높았다. 추출된 PET과 CT image texture feature를 함께 사용하여 모델을 훈련하였을 때가 각각 따로 사용하였을 때 보다 예측 성능이 개선됨을 확인하였다. 추출된 영상인자가 림프절 전이를 나타내는 바이오마커로서의 가능성을 확인할 수 있었으며 이러한 연구 결과를 바탕으로 개인별 의료 영상을 기반으로 한 비소세포폐암의 치료 전략을 수립할 수 있을 것이라 기대된다.

  • PDF

Discovery to Human Disease Research: Proteo-Metabolomics Analysis

  • Minjoong Joo;Jeong-Hun Mok;Van-An Duong;Jong-Moon Park;Hookeun Lee
    • Mass Spectrometry Letters
    • /
    • v.15 no.2
    • /
    • pp.69 -78
    • /
    • 2024
  • The advancement of high-throughput omics technologies and systems biology is essential for understanding complex biological mechanisms and diseases. The integration of proteomics and metabolomics provides comprehensive insights into cellular functions and disease pathology, driven by developments in mass spectrometry (MS) technologies, including electrospray ionization (ESI). These advancements are crucial for interpreting biological systems effectively. However, integrating these technologies poses challenges. Compared to genomic, proteomics and metabolomics have limitations in throughput, and data integration. This review examines developments in MS equipped electrospray ionization (ESI), and their importance in the effective interpretation of biological mechanisms. The review also discusses developments in sample preparation, such as Simultaneous Metabolite, Protein, Lipid Extraction (SIMPLEX), analytical techniques, and data analysis, highlighting the application of these technologies in the study of cancer or Huntington's disease, underscoring the potential for personalized medicine and diagnostic accuracy. Efforts by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and integrative data analysis methods such as O2PLS and OnPLS extract statistical similarities between metabolomic and proteomic data. System modeling techniques that mathematically explain and predict system responses are also covered. This practical application also shows significant improvements in cancer research, diagnostic accuracy and therapeutic targeting for diseases like pancreatic ductal adenocarcinoma, non-small cell lung cancer, and Huntington's disease. These approaches enable researchers to develop standardized protocols, and interoperable software and databases, expanding multi-omics research application in clinical practice.